Annie Wai Yeeng Chai

Dr. Annie Wai Yeeng Chai

Cancer Research Malaysia
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Seminars in Cancer Biology
Verified
Journal Article
Closed access
Annie Wai Yeeng ChaiAnnie Wai Yeeng Chai
Annie Wai Yeeng Chai
KLKue Peng Lim
Kue Peng Lim
SCSok Ching Cheong
Sok Ching Cheong

29 September 2020 in eLife
Verified
Journal Article
Open access
Annie Wai Yeeng ChaiAnnie Wai Yeeng Chai
Annie Wai Yeeng Chai
PYPei San Yee
Pei San Yee
SPStacey Price
Stacey Price
SYShi Mun Yee
Shi Mun Yee
HLHui Mei Lee
Hui Mei Lee
SCSok Ching Cheong
Sok Ching Cheong
New therapeutic targets for oral squamous cell carcinoma (OSCC) are urgently needed. We conducted genome-wide CRISPR-Cas9 screens in 21 OSCC cell lines, primarily derived from Asians, to identify genetic vulnerabilities that can be explored as therapeutic targets. We identify known and novel fitness genes and demonstrate that many previously identified OSCC-related cancer genes are non-essential and could have limited therapeutic value, while other fitness genes warrant further investigation for their potential as therapeutic targets. We validate a distinctive dependency on YAP1 and WWTR1 of the Hippo pathway, where the lost-of-fitness effect of one paralog can be compensated only in a subset of lines. We also discover that OSCCs with WWTR1 dependency signature are significantly associated with biomarkers of favorable response toward immunotherapy. In summary, we have delineated the genetic vulnerabilities of OSCC, enabling the prioritization of therapeutic targets for further exploration, including the targeting of YAP1 and WWTR1.

26 October 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
Annie Wai Yeeng ChaiAnnie Wai Yeeng Chai
Annie Wai Yeeng Chai
ACArthur Kwok Leung Cheung
Arthur Kwok Leung Cheung
WDWei Dai
Wei Dai
JKJosephine Ko
Josephine Ko
JIJoseph Chok Yan Ip
Joseph Chok Yan Ip
MLMaria Li Lung
Maria Li Lung
Metastasis-suppressing NID2 , an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma Metastasis-suppressing NID2, an epigenetically-silenced gene, in the pathogenesis of nasopharyngeal carcinoma and esophageal squamous cell carcinoma

9 August 2019 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
JKJosephine Ko
Josephine Ko
LNLvwen Ning
Lvwen Ning
XZXue‐Ke Zhao
Xue‐Ke Zhao
Annie Wai Yeeng ChaiAnnie Wai Yeeng Chai
Annie Wai Yeeng Chai
Lisa Chan LeiLisa Chan Lei
Lisa Chan Lei
MLMaria Li Lung
Maria Li Lung
Esophageal squamous cell carcinoma (ESCC) occurs with highest frequency in China with over 90% mortality, highlighting the need for early detection and improved treatment strategies. We aimed to identify ESCC cancer predisposition gene(s). Our study included 4,517 individuals. The discovery phase using whole‐exome sequencing (WES) included 186 familial ESCC patients from high‐risk China. Targeted gene sequencing validation of 598 genes included 3,289 Henan and 1,228 moderate‐risk Hong Kong Chinese. A WES approach identified BRCA2 loss‐of‐function (LOF) mutations in 3.23% (6/186) familial ESCC patients compared to 0.21% (9/4300) in the ExAC East Asians (odds ratio [OR] = 15.89, p = 2.48 × 10−10). BRCA2 LOF mutation frequency in the combined Henan cohort has significantly higher prevalence (OR = 10.55, p = 0.0035). Results were independently validated in an ESCC Hong Kong cohort (OR = 10.64, p = 0.022). One Hong Kong pedigree was identified to carry a BRCA2 LOF mutation. BRCA2 inactivation in ESCC was via germline LOF mutations and wild‐type somatic allelic loss via loss of heterozygosity. Gene‐based association analysis, including LOF mutations and rare deleterious missense variants defined with combined annotation dependent depletion score ≥30, confirmed the genetic predisposition role of BRCA2 (OR = 9.50, p = 3.44 × 10−5), and provided new evidence for potential association of ESCC risk with DNA repair genes (POLQ and MSH2), inflammation (TTC39B) and angiogenesis (KDR). Our findings are the first to provide compelling evidence of the role of BRCA2 in ESCC genetic susceptibility in Chinese, suggesting defective homologous recombination is an underlying cause in ESCC pathogenesis, which is amenable to therapeutic options based on synthetic lethality approaches such as targeting BRCA2 with PARP1 inhibitors in ESCC.

4 March 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
Annie Wai Yeeng ChaiAnnie Wai Yeeng Chai
Annie Wai Yeeng Chai
SYShi Mun Yee
Shi Mun Yee
HLHui Mei Lee
Hui Mei Lee
NANorazlin Abdul Aziz
Norazlin Abdul Aziz
PYPei San Yee
Pei San Yee
SCSok Ching Cheong
Sok Ching Cheong
Nasopharyngeal carcinoma (NPC), a cancer that is etiologically associated with the Epstein-Barr virus (EBV), is endemic in Southern China and Southeast Asia. The scarcity of representative NPC cell lines owing to the frequent loss of EBV episomes following prolonged propagation and compromised authenticity of previous models underscores the critical need for new EBV-positive NPC models. Herein, we describe the establishment of a new EBV-positive NPC cell line, designated NPC268 from a primary non-keratinizing, differentiated NPC tissue. NPC268 can undergo productive lytic reactivation of EBV and is highly tumorigenic in immunodeficient mice. Whole-genome sequencing revealed close similarities with the tissue of origin, including large chromosomal rearrangements, while whole-genome bisulfite sequencing and RNA sequencing demonstrated a hypomethylated genome and enrichment in immune-related pathways, respectively. Drug screening of NPC268 together with six other NPC cell lines using 339 compounds, representing the largest high-throughput drug testing in NPC, revealed biomarkers associated with specific drug classes. NPC268 represents the first and only available EBV-positive non-keratinizing differentiated NPC model, and extensive genomic, methylomic, transcriptomic, and drug response data should facilitate research in EBV and NPC, where current models are limited.Significance: NPC268 is the first and only EBV-positive cell line derived from a primary non-keratinizing, differentiated nasopharyngeal carcinoma, an understudied but important subtype in Southeast Asian countries. This model adds to the limited number of authentic EBV-positive lines globally that will facilitate mechanistic studies and drug development for NPC.

14 February 2018 in Cancer Biomarkers
Verified
Journal Article
Closed access
PDF file
Annie Wai Yeeng ChaiAnnie Wai Yeeng Chai
Annie Wai Yeeng Chai
ACArthur Kwok Leung Cheung
Arthur Kwok Leung Cheung
WDWei Dai
Wei Dai
JKJosephine Ko
Josephine Ko
NLNikki Pui Yue Lee
Nikki Pui Yue Lee
MLMaria Li Lung
Maria Li Lung
BACKGROUND: Nidogen-2 (NID2), a secretory basement membrane protein, has been implicated as a potential biomarker in ovarian cancer and hepatocellular carcinoma. OBJECTIVE: In this study, we aimed to investigate the utility of detecting serum NID2 le